Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioMarin Pharmaceutical Inc.

www.bmrn.com

Latest From BioMarin Pharmaceutical Inc.

BioMarin All Set For Hemophilia Gene Therapy Approval, But Is It Overestimating Demand?

Analysts forecast a slow climb towards peak sales of $2bn – but competitors could erode that figure.

Commercial Companies

EU Accelerated Assessment Tracker

EU marketing applications from Vertex and Roche have reverted to standard review timelines at the European Medicines Agency. The outcomes of three fast-track requests that companies have made for their planned filings are still unknown.

Europe Drug Review

UK: NICE’s Rare Disease Gatekeeping Comes Under The Microscope

A judicial review of how health technology appraisal body NICE decided which appraisal route BioMarin’s rare disease drug Kuvan would take could have lasting implications for future treatments.

Europe United Kingdom

Gene Therapy Approvals By US FDA Could Double In 2020

CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.

Gene Therapy Drug Review
See All

Company Information

UsernamePublicRestriction

Register